Genetic Factors Associated with a Poor Outcome in Head and Neck Cancer Patients Receiving Definitive Chemoradiotherapy.
DNA sequence analysis
chemoradiotherapy
genomics
head and neck squamous cell carcinoma
mutation
pharyngeal neoplasms
prognosis
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
29 Mar 2019
29 Mar 2019
Historique:
received:
04
03
2019
revised:
24
03
2019
accepted:
26
03
2019
entrez:
3
4
2019
pubmed:
3
4
2019
medline:
3
4
2019
Statut:
epublish
Résumé
About half of advanced stage head and neck squamous cell carcinoma (HNSCC) patients can be cured by chemoradiotherapy. Patient outcome may be partially determined by the genetic alterations in HNSCC, rendering these alterations promising candidate prognostic factors and/or therapeutic targets. However, their relevance in patient outcome prognosis remains to be assessed in patients that receive standard-of-care chemoradiotherapy. We therefore tested whether frequent genetic alterations were associated with progression free survival (PFS) in advanced stage HNSCC patients who were uniformly treated with definitive platinum-based chemoradiotherapy. To this end, we performed targeted DNA sequencing on frozen pre-treatment tumor biopsy material from 77 patients with advanced stage oro- and hypopharyngeal carcinoma. This provided somatic point mutation and copy number aberration data of 556 genes. The most frequently mutated genes,
Identifiants
pubmed: 30934880
pii: cancers11040445
doi: 10.3390/cancers11040445
pmc: PMC6521057
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : KWF Kankerbestrijding
ID : DESIGN
Organisme : Verwelius
ID : n/a
Références
Oncogene. 1999 Jun 10;18(23):3541-5
pubmed: 10376532
Clin Cancer Res. 1999 Oct;5(10):2810-9
pubmed: 10537346
Oncogene. 2000 Jul 6;19(29):3225-34
pubmed: 10918579
Br J Cancer. 2001 Jul 6;85(1):14-22
pubmed: 11437396
Laryngoscope. 2002 Mar;112(3):472-81
pubmed: 12148857
Clin Cancer Res. 2003 May;9(5):1750-5
pubmed: 12738730
Nat Rev Cancer. 2004 Mar;4(3):177-83
pubmed: 14993899
Int J Cancer. 2004 May 1;109(5):710-6
pubmed: 14999779
Nat Rev Cancer. 2004 Oct;4(10):814-9
pubmed: 15510162
Gut. 2008 Jul;57(7):941-50
pubmed: 18364437
Bioinformatics. 2009 May 1;25(9):1105-11
pubmed: 19289445
Radiother Oncol. 2009 Jul;92(1):4-14
pubmed: 19446902
Bioinformatics. 2009 Jul 15;25(14):1754-60
pubmed: 19451168
Bioinformatics. 2009 Aug 15;25(16):2078-9
pubmed: 19505943
J Clin Oncol. 1991 Jan;9(1):191-2
pubmed: 1985169
Clin Cancer Res. 2010 Jan 1;16(1):77-87
pubmed: 20028744
Nucleic Acids Res. 2010 Sep;38(16):e164
pubmed: 20601685
Genome Res. 2012 Mar;22(3):568-76
pubmed: 22300766
J Clin Invest. 2012 Apr;122(4):1138-43
pubmed: 22466654
Science. 2012 Jul 6;337(6090):64-9
pubmed: 22604720
J Clin Invest. 2012 Jun;122(6):1951-7
pubmed: 22833868
Cancer. 2013 Aug 15;119(16):3034-42
pubmed: 23696076
Nat Genet. 2013 Oct;45(10):1127-33
pubmed: 24071851
Bioinformatics. 2015 Jan 15;31(2):166-9
pubmed: 25260700
Nature. 2015 Jan 29;517(7536):576-82
pubmed: 25631445
Ann Oncol. 2015 Jun;26(6):1216-23
pubmed: 25712460
Oncotarget. 2015 Jul 20;6(20):18066-80
pubmed: 25980437
Genome Med. 2015 Sep 23;7:98
pubmed: 26395002
Science. 2015 Sep 25;349(6255):1483-9
pubmed: 26404825
Nature. 2015 Oct 1;526(7571):68-74
pubmed: 26432245
Mol Cell. 2015 Nov 19;60(4):547-60
pubmed: 26590714
Nat Med. 2016 Jan;22(1):105-13
pubmed: 26618723
Cancer Discov. 2016 Apr;6(4):353-67
pubmed: 26658964
J Cancer Res Clin Oncol. 2016 Apr;142(4):873-83
pubmed: 26677030
Clin Cancer Res. 2016 Jun 15;22(12):2939-49
pubmed: 26763254
Nat Rev Cancer. 2016 Feb;16(2):110-20
pubmed: 26775620
Clin Cancer Res. 2016 Jun 1;22(11):2802-11
pubmed: 26813356
Eur J Cancer. 2016 Apr;57:78-86
pubmed: 26896955
Nat Rev Clin Oncol. 2016 Jul;13(7):417-30
pubmed: 27030077
N Engl J Med. 2016 Jun 9;374(23):2209-2221
pubmed: 27276561
Oral Oncol. 2016 Jul;58:41-8
pubmed: 27311401
Appl Immunohistochem Mol Morphol. 2017 Sep;25(8):566-570
pubmed: 27389554
Cell. 2016 Jul 28;166(3):740-754
pubmed: 27397505
Oncogene. 2017 Feb 9;36(6):746-755
pubmed: 27452521
Nature. 2016 Aug 17;536(7616):285-91
pubmed: 27535533
Ann Oncol. 2016 Dec;27(12):2262-2268
pubmed: 27681865
Lancet Oncol. 2017 Jan;18(1):132-142
pubmed: 27864015
PLoS Med. 2016 Dec 6;13(12):e1002162
pubmed: 27923066
Source Code Biol Med. 2016 Dec 15;11:13
pubmed: 27999612
CA Cancer J Clin. 2017 Mar;67(2):122-137
pubmed: 28128848
Oral Oncol. 2017 Mar;66:14-21
pubmed: 28249643
Cell. 2017 Nov 16;171(5):1042-1056.e10
pubmed: 29056344
Cancers (Basel). 2017 Nov 01;9(11):null
pubmed: 29104272
Eur J Cancer. 2018 Mar;91:47-55
pubmed: 29331751
Cell Rep. 2018 Apr 03;23(1):239-254.e6
pubmed: 29617664
Oncotarget. 2018 Apr 6;9(26):18198-18213
pubmed: 29719599
Oral Oncol. 2018 Jun;81:35-44
pubmed: 29884412
Cancer Res. 1995 Nov 1;55(21):4818-23
pubmed: 7585513
J Clin Epidemiol. 1995 Dec;48(12):1495-501
pubmed: 8543963
J Clin Epidemiol. 1995 Dec;48(12):1503-10
pubmed: 8543964
Leukemia. 1997 Jan;11(1):64-72
pubmed: 9001420